F-34 | Types of Thromboembolic Events and their Outcomes Among Patients with Active Lung Cancer

Lung cancer is a well-known prothrombotic state. The incidence of various venous thromboembolic events (VTE) & their effects on in-patient outcomes of lung cancer patients is under-studied. We aim to investigate this relationship. The National Readmission Database (2016-2020) was queried to identify all-cause admissions for patients with a history of lung cancer. A Propensity Score Matching (PSM) model, matched patients with history of lung cancer to patients with any other malignancy. Pearson's x2 test was applied to the PSM-matched cohorts to compare outcomes. Among 4 million all-cause hospitalizations for active lung cancer patients, about 6. 6% suffered a VTE. The majority had acute PE (3%), followed by DVT (2. 4%) and DVT with PE (1. 1%). On a propensity-matched & multivariate analysis, patients with lung cancer have a higher incidence of acute PE (3. 6% vs 1. 6%, aOR: 2. 30), DVT (3% vs 2. 6%, aOR: 1. 24) & DVT with PE (1. 5% vs 0. 8%, aOR: 1. 85) p <0. 001. Among different VTEs, the mortality was highest for acute PE (aOR: 1. 81), followed by DVT with PE (aOR: 1. 66) & DVT (aOR: 1. 64) p <0. 001. Resource utilization is also higher in lung cancers complicated by VTE, with patients suffering a DVT having the highest LOS (7 vs 4 days) & total cost of hospitalization (21, 727 vs 14, 380) p<0. 001. The readmission rates were higher for DVT compared to PE at 90-day intervals (34. 6% vs 33. 4, p: 0. 001). The rates of venous thromboembolism were significantly higher in lung cancer when compared to all other cancer patients. The mortality was highest for PE in this cohort, while healthcare-related burden and readmission rates were higher for DVT.